Hyderabad, February 25, 2025 – Telangana’s ambitions to become a global powerhouse in life sciences and healthcare took a significant leap forward at the 22nd edition of BioAsia 2025, Asia’s largest life sciences and healthcare conference. Themed “Catalysts of Change – Expanding Global Healthcare Frontiers, Transforming Healthcare with Innovation, Collaboration and Progress,” the event was inaugurated by Telangana Chief Minister A Revanth Reddy, Queensland Governor Dr. Jeannette Young, and Telangana Minister for Industries and Commerce D Sridhar Babu, alongside other dignitaries. Held in Hyderabad, the conference showcased groundbreaking investment announcements, strategic collaborations, and a vision to cement Telangana’s position as India’s life sciences capital.
A standout moment of BioAsia 2025 was the conferment of the Genome Valley Excellence Award 2025 to Dr. Patrick Tan, a globally renowned cancer researcher from Singapore. As Executive Director of PRECISE, Senior Vice Dean (Research) at Duke-NUS Medical College, and Chief Scientific Officer at the Genome Institute of Singapore, Dr. Tan’s contributions to precision medicine have earned him this prestigious recognition.
Investment Surge Signals Bright Future
The conference served as a platform for major investment announcements, underscoring Telangana’s growing appeal to global life sciences giants. The Telangana government welcomed MSD (Merck & Co.), USA, to its thriving ecosystem, highlighting Hyderabad’s unmatched technology and life sciences capabilities. Meanwhile, AGILISIUM, a Los Angeles-based firm, launched a new office at RMZ Spire in Hyderabad, accompanied by a Life Sciences and Innovation & Talent Development Lab. ALS, a global leader in testing and certification, announced plans for a state-of-the-art Bio Pharma cGMP testing lab in Genome Valley, while MEISHI PHARMA, a Lotus Company, revealed its second R&D center in Hyderabad under its new Indian subsidiary, MEISHI Pharma Services Pvt Ltd.
A flagship initiative, the Green Pharma City, saw significant momentum with Memoranda of Understanding (MoUs) signed with 11 additional pharmaceutical companies—Granules, Orbicular, Aizant, Biological E, Virchow, Virupaksha, Jubilant, Vimta, Aragen, Bharat Biotech, and Sai Life Sciences—bringing an investment of Rs. 5,445 crore and creating 9,800 new jobs. Combined with earlier commitments from six companies, the total investment in Green Pharma City now stands at Rs. 11,100 crore, promising over 22,300 employment opportunities.
Strategic Partnerships to Drive Innovation
Telangana solidified its global standing through strategic collaborations unveiled at BioAsia 2025. A Letter of Intent was signed with the University of Queensland and Telangana Life Sciences to foster cutting-edge research in digital healthcare and AI-driven innovations. The state also became the first hub under the World Economic Forum’s Indian Digital Health Activator, a pioneering initiative to boost public-private collaboration in digital health.
The Innovative Pharmaceutical Services Organization (IPSO) was launched, uniting 11 leading contract research and development organizations to advance the CRDMO industry, nurture talent, and strengthen the global supply chain. Additionally, a partnership between I Health Innovation Manchester and T-Hub aims to drive breakthroughs in healthcare, MedTech, diagnostics, and digital health solutions.
Leadership Vision for a Life Sciences Powerhouse
Chief Minister A Revanth Reddy emphasized Hyderabad’s legacy of excellence in healthcare and biosciences, positioning BioAsia as a catalyst for India’s rise in the global healthcare sector. “We will develop Hyderabad and Telangana into one of the largest ecosystems for biosciences, biotech, and life sciences innovation, R&D, manufacturing, skill development, and investment,” he said. He highlighted ambitious infrastructure projects, including a 360-km Regional Ring Road and 10 pharma villages between the Outer Ring Road (ORR) and RRR, expected to generate over 5 lakh jobs. A forthcoming Life Sciences Policy will further propel Telangana into domains like cell and gene therapy, genomics, and precision medicine.
Minister D Sridhar Babu echoed this optimism, noting that BioAsia has become a cornerstone of the industry over two decades. “In the past 12 months, we’ve witnessed a surge of investment from international and domestic companies choosing Telangana as their gateway to India,” he said. With over 51,000 direct and 1.5 lakh indirect jobs created recently, initiatives like the Young India Skills University and a proposed Life Sciences University aim to equip the workforce with globally competitive skills.
Thought Leadership and Global Dialogue
The inaugural day featured four panel discussions, bringing together global experts. Topics ranged from AI transformation in healthcare—featuring Medtronic’s CTO Dr. Ken Washington and AIG’s Dr. Nageshwar Reddy—to the future of the Indian CRDMO sector and innovations shaping the global life sciences landscape. A CEO Conclave, “India’s Century: Leading the Global Innovation Charge in Life Sciences,” included luminaries like Dr. S Somanath, former ISRO Chairman, and G.V. Prasad of Dr. Reddy’s Laboratories.
As BioAsia 2025 unfolds, Telangana’s bold strides in infrastructure, investment, and innovation signal its readiness to lead the global life sciences frontier, transforming healthcare for generations to come.
